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Abstract
Aims/hypothesis Physical activity improves oxidative capaci-
ty and exerts therapeutic beneficial effects, particularly in the
context of metabolic diseases. The peroxisome proliferator-
activated receptor (PPAR) γ coactivator-1α (PGC-1α) and the
nuclear receptor PPARβ/δ have both been independently
discovered to play a pivotal role in the regulation of oxidative
metabolism in skeletal muscle, though their interdependence
remains unclear. Hence, our aim was to determine the func-
tional interaction between these two factors in mouse skeletal
muscle in vivo.
Methods Adult male control mice, PGC-1α muscle-specific
transgenic (mTg) mice, PPARβ/δ muscle-specific knockout
(mKO) mice and the combination PPARβ/δmKO + PGC-1α
mTg mice were studied under basal conditions and following
PPARβ/δ agonist administration and acute exercise. Whole-
body metabolism was assessed by indirect calorimetry and
blood analysis, while magnetic resonance was used to mea-
sure body composition. Quantitative PCR and western blot
were used to determine gene expression and intracellular
signalling. The proportion of oxidative muscle fibre was de-
termined by NADH staining.
Results Agonist-induced PPARβ/δ activation was only
disrupted by PPARβ/δ knockout. We also found that the
disruption of the PGC-1α–PPARβ/δ axis did not affect
whole-body metabolism under basal conditions. As expected,
PGC-1α mTg mice exhibited higher exercise performance,
peak oxygen consumption and lower blood lactate levels
following exercise, though PPARβ/δ mKO + PGC-1α mTg
mice showed a similar phenotype. Similarly, we found that
PPARβ/δ was dispensable for PGC-1α-mediated enhance-
ment of an oxidative phenotype in skeletal muscle.
Conclusions/interpretation Collectively, these results indicate
that PPARβ/δ is not an essential partner of PGC-1α in the
control of skeletal muscle energy metabolism.
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Introduction
The regulation of energy metabolism in skeletal muscle is
highly controlled by the peroxisome proliferator-activated
receptor (PPAR) γ coactivator-1α (PGC-1α) [1]. PGC-1α
drives the expression of genes involved in catabolic processes
leading to aerobic ATP synthesis [1] while concomitantly
promoting anabolic processes, including de novo lipogenesis
[2]. Once activated, PGC-1α boosts the activity of different
transcription factors to control gene programmes resembling
an endurance-trained phenotype in skeletal muscle [1, 3].
These adaptations are associated with an enhanced oxidative
capacity, which contributes to an increased skeletal muscle
fatigue resistance ex vivo and exercise performance in vivo
[4–6]. Importantly, exercise is in fact one of the most efficient
stimuli to induce PGC-1α in skeletal muscle [3].
Among the transcription factors regulated by PGC-1α, the
nuclear receptor PPARβ/δ has been proposed to be a key
partner of PGC-1α in the regulation of skeletal muscle me-
tabolism and function, though mainly based on cell culture
and pharmacological studies [7]. PGC-1α acts as a coactivator
of PPARβ/δ [8–10], while PPARβ/δ can directly regulate
PGC-1α expression [11, 12], indicating that this nuclear re-
ceptor acts both upstream and downstream of PGC-1α. Fur-
thermore, transgenic mouse models for PPARβ/δ exhibit a
similar phenotype to their counterparts for PGC-1α [4, 5, 13,
14]. Nevertheless, although the PGC-1α–PPARβ/δ axis ap-
pears to play a key role in the regulation of energy metabo-
lism, the epistatic interaction between these proteins is cur-
rently unclear. We therefore aimed at directly assessing the
functional interplay between PGC-1α and PPARβ/δ in the
regulation of skeletal muscle oxidative metabolism in vivo.
Methods
Animals Mice were housed in a conventional facility with a
12 h night/day cycle and had free access to food/water. Ex-
periments were performed on adult male mice with approval
of the Swiss authorities. PGC-1α muscle-specific transgenic
(mTg) mice have been described previously [5]. PPARβ/δ
muscle-specific knockout (mKO) mice were generated by
crossingPPARβ/δloxP/loxP mice with HSA-Cre transgenic mice
[11]. Finally, PGC-1α mTg and HSA-Cre positive PPARβ/
δloxP/loxPmKOmice were crossed to generate PPARβ/δmKO +
PGC-1α mTg mice. PPARβ/δloxP/loxP mice without Cre and
Pgc-1α (also known as Ppargc1a) transgene expression were
used as control (CON) mice. All mice had mixed sv129 and
C57BL/6 background. Genotypes were confirmed through PCR
procedures (data not shown) and quantitative PCR analysis in
kidney and skeletal muscle (Fig. 1a, b).
PPARβ/δ agonist administration CONmice were subjected to
an intraperitoneal injection of either 0.9% NaCl (control) or
1 mg/kg of body weight of the PPARβ/δ agonist GW0742
(Tocris No. 2229; Tocris, Bristol, UK), as previously de-
scribed [15]. Muscles were collected 8 h following drug
administration.
Body composition analysis Lean and fat mass were measured
via magnetic resonance imaging (EchoMRI, Houston, TX,
USA).
Blood and plasma analysis Blood samples were collected
under basal conditions or immediately after maximal exercise
from fed and/or overnight-fasted mice, as previously
described [9].
Fig. 1 PGC-1α and PPARβ/δmousemodels. (a, b)Pparβ/δ and Pgc-1α
mRNA levels in kidney, gastrocnemius (GAS) and tibialis anterior (TA)
(n=6 per group). (c, d) Pparβ/δ,Ucp3 and Angptl4mRNA levels in GAS
and plantaris (PL) 8 h after the injection of 0.9% NaCl (as control) or
1 mg/kg of body weight of the PPARβ/δ agonist GW0742 (n=6 per
group). (e) mRNA level of different transcriptional regulators inGAS (n=
6 per group). In (a), (b) and (e): white bars, CON; hatched bars, PPARβ/δ
mKO; grey bars, PGC-1α mTg; black bars, PPARβ/δ mKO + PGC-1α
mTg. In (c) and (d): white bars, CON + NaCl; black bars,
PPARβ/δ mKO + NaCl; grey bars, CON + GW0742; hatched bars,
PPARβ/δ mKO + GW0742. Values are mean ± SEM. *p<0.05,
**p<0.01 and ***p<0.001 for the indicated comparisons. In (a), (c) and
(d) ***p<0.001 vs CON and/or PGC-1α mTg for same tissue/treatment.
When shown, fold changes are reported vs CON group
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Glucose and insulin tolerance test Intraperitoneal glucose
tolerance tests (GTTs) were carried out by injecting 2 g/kg
of body weight of glucose after mice had been fasted for 16 h.
Insulin tolerance tests (ITTs) were performed by injecting
0.8 U/kg of body weight of insulin (Novo Nordisk,
Bagsvaerd, Denmark) after mice had been fasted for 6 h.
Indirect calorimetry Mice were individually housed in a
Comprehensive Lab Animal Monitoring System (Columbus
Instruments, Columbus, OH, USA) for an acclimatisation
period of 48 h during which they were allowed free access
to food and water. Subsequently, indirect calorimetry was
performed for 48 h and data was analysed with the Oxymax
software (Columbus Instruments).
Maximal exercise test Exercise tests were performed as previ-
ously described [9]. Briefly, 2 days after acclimatisation, mice
performed a maximal exercise test in a closed treadmill (Colum-
bus Instruments), allowing the measurement of peak oxygen
consumption (V
⋅
O2peak ) and respiratory exchange ratio (RER;
CO2 produced divided by consumed O2[V
⋅
CO2 /V
⋅
O2]).
Histology NADH staining was performed on 10 μm cross
sections from tibialis anterior by exposing the sections to
1 mg/ml NADH (Sigma, St Louis, MO, USA) in the presence
of 1 mg/ml nitro blue tetrazolium (Sigma).
NEFA measurement Plasma NEFA were measured using a
commercial kit (HR Series NEFA-HR(2); Wako Diagnostics,
Richmond, VA, USA), according to the manufacturer’s instruc-
tions. Blood samples were collected under basal conditions and
following 1 h of treadmill running at 13 m/min with 5° slope.
Intramyocellular triacylglycerol extraction Quadriceps
intramyocellular triacylglycerols (IMTGs) were extracted by
standard procedures using a solid-phase extraction column
(UPTI-CLEANNH2-S 100mg/1mL SPEColumns; Interchim,
Montluçon, France) and quantified with a commercial kit (Tri-
glyceride enzymatique PAP 150; Biomérieux, Marcy-l’Etoile,
France), according to the manufacturer’s instructions.
RNA isolation and quantitative PCR Total RNA isolation
from fed (ad libitum) mice and quantitative PCR (qPCR)
analysis was performed by standard procedures [9]. Se-
quences of qPCR primers are depicted in electronic supple-
mentary material (ESM) Table 1. Analysis was performed by
the ΔΔCt method using TATA binding protein (TBP) as
endogenous control. TBP transcript levels were not different
between genotypes or between experimental conditions.
Protein isolation and western blot Protein isolation and west-
ern blot was conducted as previously described [9]. Proteins
were detected with primary antibodies to Akt (Cell Signaling
No.9272; Cell Signaling, Danvers, MA, USA), p-AktT308
(Cell Signaling No. 4056), AMP-activated protein kinase
(AMPK) α (Cell Signaling No. 2603), p-AMPKαT172 (Cell
Signaling No. 2535), total OXPHOS (ab110413; Abcam,
USA) and eEF2 (Cell Signaling No. 2332).
Statistical analysis Values are expressed as mean ± SEM.
Statistical significance was determined with unpaired two-
tailed t tests or one-way ANOVAwith Tukey’s post hoc test.
Significance was considered with a p<0.05.
Results
PGC-1α overexpression and PPARβ/δ deletion in mouse skel-
etal muscle To elucidate the functional requirement for
PPARβ/δ in the metabolic adaptations induced by PGC-1α,
we crossed PPARβ/δ mKO mice with PGC-1α mTg mice,
referred to as PPARβ/δ mKO + PGC-1α mTg mice. As
expected, both PPARβ/δ mKO and PPARβ/δ mKO + PGC-
1αmTg mice showed a reduction in Pparβ/δ (Ppard) mRNA
specifically in skeletal muscle, while Pgc-1α mRNA was
upregulated by∼12-fold in skeletal muscle of PGC-1α mTg
and PPARβ/δ mKO + PGC-1α mTg mice compared with
control (CON) mice (Fig. 1a, b). To validate the functional
consequence of Pparβ/δ deletion in skeletal muscle, we
assessed the effects of the PPARβ/δ agonist GW0742 on the
expression levels of PPARβ/δ target genes [7, 16]. Acute
treatment with GW0742 did not affect Pparβ/δ mRNA in
gastrocnemius and plantaris muscles whereas Ucp3 mRNA
levels were induced in CON, but not in PPARβ/δ mKO mice
(Fig. 1c, d). Moreover, as previously reported [16], Angptl4
was upregulated by GW0742 in a way that was partially
dependent on PPARβ/δ (Fig. 1c, d). Importantly, Pparβ/δ
deletion did not affect the transcript levels of Pparα (Ppara)
and Pparγ (Pparg) (Fig. 1e). We subsequently measured the
expression levels of other transcription factors and
coactivators regulating metabolism, including the oestrogen-
related receptors, mitochondrial transcription factor A, Pgc-
1β and PGC-1-related coactivator. The expression levels of
genes encoding these factors/coactivators (Errα [Esrra], Errβ
[Esrrb], Tfam, Pgc-1β [Ppargc1b], Prc [Pprc1]) were altered
in skeletal muscle of PGC-1α mTg and PPARβ/δ mKO +
PGC-1α mTg mice, thus independent of PPARβ/δ ablation
(Fig. 1e).
Effects of skeletal muscle disruption of the PGC-1α–PPARβ/δ
axis on whole-body metabolism Body composition assess-
ment revealed equal body weight, fat mass and lean mass in
PPARβ/δ mKO, PGC-1α mTg, PPARβ/δ mKO + PGC-1α
mTg and CONmice (Fig. 2a). Analysis of plasma triacylglyc-
erol, cholesterol, LDL-cholesterol and HDL-cholesterol
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during the fed and fasted state exhibited no differences except
for a significant decrease in fed cholesterol in the PPARβ/δ
mKO + PGC-1α mTg mice (Fig. 2b, c). Moreover, indirect
calorimetry during 48 h revealed no differences in V
⋅
O2 or
RER between any of the genotypes (Fig. 2d, e and ESM
Fig. 1a, b).
Pharmacological activation of PPARβ/δ attenuates the det-
rimental effects of obesity and type 2 diabetes on systemic
glucose homeostasis [13, 17, 18]. Compared with CON mice,
neither GTTs nor ITTs were affected by PGC-1α overexpres-
sion and/or Pparβ/δ deletion in skeletal muscle in mice fed a
regular chow diet (Fig. 2f, g and ESM Fig. 1c, d). Moreover,
we did not find any differences in blood glucose levels in fed
mice between the four different genotypes (Fig. 2h). These
findings were corroborated by unchanged expression of genes
involved in glucose transport and catabolism, such as Glut4
(Slc2a4), Tbc1d1, Pfk and Hk2 (encoding glucose transporter
4, TBC domain family member 1, phosphofructokinase and
hexokinase 2, respectively), in skeletal muscle of PPARβ/δ
mKO, PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg
mice (Fig. 2i). In contrast, Tbc1d4 (As160, and which encodes
Akt substrate of 160 kDa) was significantly upregulated in
PGC-1α mTg mice (Fig. 2i). Finally, we observed an increase
in total Akt protein levels following PGC-1α overexpression,
with no substantial effect of Pparβ/δ deletion (Fig. 2j and ESM
Fig. 1e). Consistently, PGC-1α overexpression slightly de-
creased relative AktT308 phosphorylation levels, although this
effect was not statistically significant (ESM Fig. 1f). These
data hence suggest that the PGC-1α–PPARβ/δ axis is not
essential for the modulation of whole-body metabolism and
glucose homeostasis under basal conditions in chow-fed mice.
Modulation of skeletal muscle metabolism by the PGC-1α–
PPARβ/δ axis Skeletal muscle PGC-1α and PPARβ/δ have
been proposed to be key regulators of exercise performance
and lactate metabolism [19, 20]. Consequently, we next
assessed exercise performance in treadmill-based tests, which
revealed a higher exercise performance in PGC-1αmTg mice
as expected (Fig. 3a–c). Interestingly, Pparβ/δ muscle knock-
out did not reduce this difference when PPARβ/δ mKO +
PGC-1αmTgmice were compared with CONmice (Fig. 3a–c).
Moreover, V
⋅
O2 was significantly enhanced in PGC-1α mTg
Fig. 2 Body composition, systemic variables and glucose handling. (a)
Assessment of body composition (n=10–12 mice per group). (b, c)
Plasma concentration of TG, cholesterol (Chol), LDL-cholesterol and
HDL-cholesterol under fed and fasted conditions (n=10–12 mice per
group). (of V
⋅
O2 (d) and RER (e) over a period of 48 h (n=10–14
mice per group). (f, g) Blood glucose levels during GTTs (f) and
ITTs (g). (h) Blood glucose levels in fed mice (n=10–12 per group).
(i) Gastrocnemius mRNA levels of genes involved in glucose
metabolism (n=6 mice per group). (j) Western blot assessment of Akt
phosphorylation status in gastrocnemius muscle (n=6 mice per group). In
(a–c), (h) and (i): white bars, CON; hatched bars, PPARβ/δ mKO; grey
bars, PGC-1α mTg; black bars, PPARβ/δ mKO + PGC-1α mTg.
*p<0.05 and **p<0.01 for the indicated comparisons. In (d–g): solid
black line, CON; dashed black line, PPARβ/δ mKO; solid grey line,
PGC-1α mTg; dashed grey line, PPARβ/δ mKO + PGC-1α mTg.
†p<0.05, PPARβ/δ mKO vs PGC-1α mTg; ‡‡‡p<0.001 PPARβ/δ
mKO vs PPARβ/δ mKO + PGC-1α mTg. In graphs, values are mean ±
SEM. When shown, fold changes are reported vs CON group
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and PPARβ/δ mKO + PGC-1α mTg mice during maximal
exercise (Fig. 3d), thus altered by PGC-1α independent of
PPARβ/δ. In contrast, the decrease in the RER in PGC-1α
mTg mice was attenuated by concomitant Pparβ/δ deletion
(Fig. 3e). Blood lactate concentration increased following
maximal exercise in CON mice (Fig. 3f). This effect was
attenuated in PPARβ/δ mKO mice and virtually abolished in
both PGC-1αmTg and PPARβ/δmKO + PGC-1αmTg mice
(Fig. 3f). Similarly, pre-exercise blood lactate levels were
reduced only in the mouse models with elevated skeletal
muscle PGC-1α (Fig. 3f). Consistently, mRNA levels of
genes encoding lactate dehydrogenase A (Ldha) and mono-
carboxylic acid transporter 4 (Mct4 [Slc16a3]) were reduced
only by PGC-1α overexpression in skeletal muscle, while in
the same mice, Ldhb and Mct1 (Slc16a1) genes were upreg-
ulated (Fig. 3g), reflecting an attenuated lactate production as
well as higher catabolism. To assess substrate availability, we
measured IMTG content and, consistent with the function of
PGC-1α in de novo lipogenesis [2], both PGC-1α mTg and
PPARβ/δmKO+ PGC-1αmTgmice showed elevated IMTG
levels, though Pparβ/δ knockout had no effect (Fig. 3h).
Finally, we measured plasma levels of NEFA before and after
exercise. Exercise significantly increased plasma NEFA levels
in PPARβ/δ mKO mice, while CON and PPARβ/δ mKO +
PGC-1α mTg mice showed a trend toward an increase
(Fig. 3i). These data show that, in response to maximal exer-
cise, skeletal muscle PGC-1α is a pivotal regulator of whole-
body metabolism, mainly in a PPARβ/δ-independent manner.
Next, we investigated the relevance of PGC-1α and
PPARβ/δ interaction in the regulation of skeletal muscle
metabolism. We therefore determined the mRNA levels of
genes regulating skeletal muscle oxidative metabolism, sev-
eral of which have been suggested to be both PGC-1α and
PPARβ/δ targets. Interestingly, we observed that Pparβ/δ
deletion in skeletal muscle did not change the transcript abun-
dance of genes involved in the tricarboxylic acid cycle,
β-oxidation and electron transport chain (Fig. 4a, b). In con-
trast, most of these genes were strongly upregulated by
PGC-1α overexpression in a PPARβ/δ-independent manner
(Fig. 4a, b). Assessment of the protein content of different
components of mitochondrial complexes supported the
mRNA data, although the overall effects were milder
Fig. 3 Skeletal muscle PGC-1α modulates whole-body metabolism in
mice during maximal exercise. (a–c) Maximal speed, time and work
achieved during exercise tests to exhaustion (n=10–12 mice per group).
(d, e) Measurement of V
⋅
O2 and RER during the maximal exercise test
(n=10–12 mice per group). (f) Blood lactate levels before (Pre) and after
(Post) maximal exercise (n=10–12 mice per group). (g) mRNA levels of
key genes of lactate metabolism in gastrocnemius (n=6 per group). (h)
Quadriceps IMTG content (n=5 per group). (i) Plasma levels of NEFA
before (Pre) and after (Post) exercise (n=4–6 mice per group). Values are
mean ± SEM. In (a–c, f–i): white bars, CON; hatched bars, PPARβ/δ
mKO; grey bars, PGC-1α mTg; black bars, PPARβ/δ mKO + PGC-1α
mTg. In (d, e): black continuous line, CON; black discontinuous line,
PPARβ/δmKO; grey continuous line, PGC-1αmTg; grey discontinuous
line, PPARβ/δ mKO + PGC-1α mTg. *p<0.05, **p<0.01 and
***p<0.001 for the indicated comparisons. In (d, e): †p<0.05,
††p<0.01 and †††p<0.001, CON vs PGC-1α mTg; ‡‡p<0.01, PPARβ/δ
mKO vs PPARβ/δ mKO + PGC-1α mTg; §p<0.05 and §§§p<0.001,
PPARβ/δ mKO vs PGC-1α mTg; ¶p<0.05 and ¶¶p<0.01, CON vs
PPARβ/δ mKO + PGC-1α mTg. In (i) ¥p=0.067; ¤p=0.065. When
shown, fold changes are reported vs CON group
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(Fig. 4c and ESM Fig. 2a). We then assessed the metabolic
muscle phenotype by determining the proportion of oxidative
fibre using NADH staining. This revealed a higher oxidative
activity and proportion of oxidative fibres in PGC-1α mTg
and PPARβ/δ mKO + PGC-1α mTg mice independent of a
functional Pparβ/δ gene (Fig. 4d). The total protein content
and phosphorylation levels of the key metabolic regulator
AMPK did not differ between PPARβ/δ mKO, PGC-1α
mTg and PPARβ/δ mKO + PGC-1α mTg mice, suggesting
that there was no alteration in energy status in any of these
models (Fig. 4e and ESM Fig. 2b, c). We finally explored the
relevance of the PGC-1α–PPARβ/δ axis in the context of the
PPARβ/δ agonist GW0742-induced gene expression. As
shown in ESM Fig. 2d, GW0742 enhanced the expression
of the PPARβ/δ target genes Angptl4 andUcp3, whereas it did
not affect the mRNA levels of the key regulators of oxidative
metabolism. Moreover, the effects of PGC-1α overexpression
on gene expression were not affected by GW0742 (ESM
Fig. 2d). Finally, as expected, Pparβ/δ gene ablation likewise
abrogated any effect of the synthetic ligand (Fig. 1c, d and
ESM Fig. 2d).
Discussion
The oxidative phenotype of skeletal muscle is strongly linked
to physical activity levels and it has been associated with
beneficial health effects in metabolic diseases and other pa-
thologies. Even though the molecular mechanisms controlling
exercise-induced adaptation in skeletal muscle have not been
fully elucidated, PGC-1α is thought to promote mitochondrial
function, myofibrillar gene expression, vascularisation and
other gene programmes that are characteristic of oxidative
muscle fibres [1]. Interestingly, PPARβ/δ is able to recapitu-
late several of these effects [7], although the functional inter-
action between PGC-1α and PPARβ/δ has not been elucidat-
ed in this tissue so far. We now provide strong evidence
indicating the almost complete PPARβ/δ independence of
PGC-1α overexpression in its effects on the metabolic phe-
notype of skeletal muscle.
Importantly, supporting our hypothesis, contrary to the
effects observed in PGC-1α muscle-specific transgenic mice,
the enhancement of skeletal muscle oxidative metabolism is
weaker in a bona fide muscle-specific PPARβ/δ gain-of-
function mouse model [14]. Moreover, ligand-based activa-
tion of PPARβ/δ only increases exercise performance in
trained mice and not in sedentary animals [10]. Interestingly,
oxidative metabolism and exercise performance can be
boosted by fusing the PPARβ/δ protein to the heterologous
VP16 activation domain, which strongly increases its tran-
scriptional activity in the absence of ligand or coactivator
recruitment [13]. These data demonstrate that the reported
functions of PPARβ/δ upstream and downstream of
PGC-1α thereby are dispensable for PGC-1α function in an
overexpression context. These observations are consistent
Fig. 4 Oxidative metabolism of gastrocnemius is enhanced by PGC-1α
even in the absence of PPARβ/δ. (a, b) mRNA levels of genes regulating
oxidative and fatty acid metabolism (n=6 per group). (c) Western blot
analysis of key proteins regulating the electron transport chain (n=6 per
group). (d) Assessment of oxidative muscle fibres (dark blue) via NADH
staining (n=3 per group). (e) Western blot analysis of AMPK
phosphorylation status (n=6 per group). In (a, b): white bars, CON;
hatched bars, PPARβ/δ mKO; grey bars, PGC-1α mTg; black bars,
PPARβ/δ mKO + PGC-1α mTg. Values are mean ± SEM. *p<0.05,
**p<0.01 and ***p<0.001 for the indicated comparisons. When shown,
fold changes are reported vs CON group
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with cell culture-based experiments showing that PGC-1α
strongly increases oxidative metabolism in the absence of
PPARβ/δ in skeletal muscle cells [21]. It thus appears that
PGC-1α regulates skeletal muscle oxidative metabolism by
increasing the transcriptional activity of alternative transcrip-
tion factors, some of which might even compensate for the
loss of PPARβ/δ. In fact, Pparα, Errα and Errγ were signif-
icantly upregulated in the skeletal muscle of both PGC-1α
mTg and PPARβ/δ mKO + PGC-1α mTg mice, suggesting
that these transcription factors might have a more relevant
function in this context. Importantly, our results indicate that
Pparβ/δ deletion by itself does not result in a compensatory
activation of such related transcription factors. In fact, PPARβ/δ
mKOmice do not exhibit an upregulation of PPARs, oestrogen-
related receptors or mitochondrial transcription factor A in
skeletal muscle. In addition, several target genes of these tran-
scription factors were unaltered in PPARβ/δ mKO mice.
The contribution of PPARβ/δ to the regulation of skeletal
muscle metabolism seems to be more relevant in the context of
ligand-induced activation. Accordingly, PPARβ/δ activation
with synthetic ligands is an efficient treatment for metabolic
disorders [13, 17, 18, 22], though it remains unclear whether
this effect is mediated by skeletal muscle PPARβ/δ. Converse-
ly, overexpression of PGC-1α in skeletal muscle is insufficient
to evoke similar therapeutic benefits in young mice and even
accelerates the development of insulin resistance when such
mice are fed a high-fat diet [23], unless the mice are concom-
itantly exercised [24]. In elderly animals, however, overexpres-
sion of PGC-1α in muscle prevents age-induced insulin resis-
tance [25]. These findings indicate that in some pathological
settings, PPARβ/δ activation might be more relevant than
PGC-1α, particularly in the absence of physical activity.
Surprisingly, in our study, PPARβ/δ mKO mice had a
similar phenotype to CON mice, with minimal or no changes
in body composition, blood variables and gene expression. In
contrast, Schuler et al have reported higher bodyweight and fat,
in addition to increased serum levels of glucose, insulin and
TG, in the same mouse model [11]. Intriguingly, similar dis-
crepancies have been reported in global PPARβ/δ KO mouse
models in regard to whole-body metabolism assessed under
basal conditions [18, 26–29]. These differences in the pheno-
type of PPARβ/δKOmouse models in the chow-fed sedentary
condition might stem from different environmental factors (e.g.
diet and temperature), which could lead to a partial PPARβ/δ
activation in CON mice and thus lead to more pronounced
phenotypic differences in metabolic variables when compared
with knockout mice. Importantly, most of the effects of skeletal
muscle Pparβ/δ deletion reported by Schuler et al on energy
metabolism are observed following high-fat diet feeding and/or
in elderly mice [11]. Moreover, in the same study, the pheno-
type of adult PPARβ/δmKO mice fed chow diet is rather mild
and not substantially different from our results, reflected by the
magnitude and variability of the data [11].
During exercise, skeletal muscle exerts a greater impact on
whole-body metabolism. Accordingly, PGC-1α mTg mice
exhibit a higher V
⋅
O2 and lower RER during treadmill run-
ning, reflecting an enhanced oxidative capacity and increased
fatty acid oxidation [4]. Interestingly, while the PGC-1α-
mediated improvement in V
⋅
O2 during exercise was main-
tained in the absence of a functional PPARβ/δ gene, knockout
of Pparβ/δ attenuated the decrease in the RER in PPARβ/δ
mKO + PGC-1α mTg mice. In line with our observations, it
has been shown that PPARβ/δ overexpression in skeletal
muscle does not affect V
⋅
O2 and RER during treadmill run-
ning [20]. Moreover, PPARβ/δ has been proposed to specif-
ically regulate fatty acid metabolism and, only to a smaller
extent, other oxidative metabolic genes in cultured muscle
cells [21]. Surprisingly, the effect of PPARβ/δ knockout on
RER during maximal exercise appears to be unrelated to
mRNA level of genes controlling fatty acid transport and
oxidation. Interestingly, Pparβ/δ deletion attenuated the up-
regulation of Pdk4 induced by PGC-1α overexpression. Im-
portantly, skeletal muscle pyruvate dehydrogenase kinase 4
has been extensively shown to be a key regulator of fatty acid
oxidation during exercise [30], suggesting a possible mecha-
nism by which PPARβ/δ modulates RER and thus energy
substrate use during maximal exercise. It should be noted that
Pparβ/δ knockout induced the upregulation of Pdk4, an effect
that supports the idea that this nuclear receptor can actively
repress target genes in the absence of ligand [16, 31].
Together, these data suggest that the effects of skeletal
muscle PGC-1α on V
⋅
O2 are not dependent upon PPARβ/δ,
even though this nuclear receptor appears to be partially
involved in the PGC-1α-mediated increase in β-oxidation
during exercise. In addition, our findings support previous
data suggesting that PGC-1α-controlled lactate metabolism
is predominantly regulated by oestrogen-related receptor α
and not by PPARβ/δ [19].
In summary, our results reveal important insights into the
regulatory networks that control skeletal muscle plasticity.
Here, we show that in normal/physiological conditions,
PPARβ/δ is dispensable for the effect of PGC-1α on skeletal
muscle remodelling. Importantly, the different therapeutic
effects of PPARβ/δ and PGC-1α in the context of metabolic
diseases during sedentary vs exercise/ageing state, strongly
suggest that the relative importance of these molecules in
controlling the metabolic phenotype of skeletal muscle varies
significantly depending on the physiological and pathological
context. Therefore, we hope that these findings will allow a
more targeted dissection and modulation of skeletal muscle
plasticity in health and disease in the future.
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